IMS 2023 | Evidence supporting MRD-guided treatment breaks in MM
In this video, Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, outlines findings of the GEM2014MAIN trial (NCT02406144) and the MASTER trial (NCT03224507), which support the use of measurable residual disease (MRD)-guided treatment breaks in patients with multiple myeloma (MM). Further clinical trials are currently in progress to provide additional data in this area and to allow clinicians to use MRD-status as a basis for making clinical decisions in regard to patients terminating treatment. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
